{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:18:41Z","timestamp":1766999921117,"version":"3.48.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ministero della Salute"],"award-info":[{"award-number":["Ministero della Salute"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Following the exposure to toxic therapeutic agents employed in the treatment of malignancies, endocrine complications can affect up to 40\u201360% of childhood cancer survivors (CCS), with central hypothyroidism (CeH) being a relevant adverse event observed in this population. Given the long-standing uptrend in the number of CCS due to advances in antineoplastic and support therapies, the issue of treatment-related endocrine disorders, including CeH, has become an increasingly relevant topic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pubmed search carried out using an ad-hoc query string in January 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main results<\/jats:title>\n                    <jats:p>The pathophysiology of CeH in CCS is primarily related to damage to the hypothalamic-pituitary-thyroid axis, often caused by the synergetic detrimental effect of antineoplastic treatments. Understanding the pathogenesis and the specificities of iatrogenic CeH is crucial to improve the clinical management of CCS. Due to the often subtle and paucisymptomatic nature of CeH in its early stages, regular, life-long thyroid screening is essential to prompt timely diagnosis. Indeed, early identification of CeH allows for appropriate thyroid hormone replacement, which is crucial for preventing long-term metabolic and developmental complications and to improve the quality of life of these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review aims to enhance awareness among healthcare providers regarding the critical importance of timely detection of CeH and its specificities among CCS, in order to better understand the pathogenesis of treatment-related CeH and to outline evidence-based strategies for the diagnosis and treatment of CeH in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-025-02659-5","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:16:42Z","timestamp":1753679802000},"page":"2577-2587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on diagnostic and therapeutic challenges of central hypothyroidism among childhood cancer survivors"],"prefix":"10.1007","volume":"48","author":[{"given":"Alice","family":"Casiraghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Cattoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2068-9581","authenticated-orcid":false,"given":"Luca","family":"Persani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2659_CR1","doi-asserted-by":"publisher","unstructured":"Shapiro CL (2018) Cancer Survivorship. Longo DL, ed. New Eng J Med 379(25):2438\u20132450. https:\/\/doi.org\/10.1056\/NEJMra1712502","DOI":"10.1056\/NEJMra1712502"},{"issue":"6","key":"2659_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrendo.2016.45","volume":"12","author":"SR Rose","year":"2016","unstructured":"Rose SR, Horne VE, Howell J et al (2016) Late endocrine effects of childhood cancer. Nat Rev Endocrinol 12(6):319\u2013336. https:\/\/doi.org\/10.1038\/nrendo.2016.45","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2659_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-8587(24)00088-3","volume":"12","author":"CS Link-Rachner","year":"2024","unstructured":"Link-Rachner CS, G\u00f6bel A, Jaschke NP, Rachner TD (2024) Endocrine health in survivors of adult-onset cancer. Lancet Diabetes Endocrinol 12(5):350\u2013364. https:\/\/doi.org\/10.1016\/S2213-8587(24)00088-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2659_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000491388","volume":"7","author":"L Persani","year":"2018","unstructured":"Persani L, Brabant G, Dattani M et al (2018) 2018 European thyroid association (ETA) guidelines on the diagnosis and management of central hypothyroidism. Eur Thyroid J 7(5):225\u2013237. https:\/\/doi.org\/10.1159\/000491388","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2659_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.radonc.2015.01.016","volume":"114","author":"S Scoccianti","year":"2015","unstructured":"Scoccianti S, Detti B, Gadda D et al (2015) Organs at risk in the brain and their dose-constraints in adults and in children: A radiation oncologist\u2019s guide for delineation in everyday practice. Radiother Oncol 114(2):230\u2013238. https:\/\/doi.org\/10.1016\/j.radonc.2015.01.016","journal-title":"Radiother Oncol"},{"issue":"2","key":"2659_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ijrobp.2023.04.024","volume":"119","author":"G Wheeler","year":"2024","unstructured":"Wheeler G, Grassberger C, Samers J et al (2024) Central endocrine complications among childhood Cancer survivors treated with radiation therapy: A PENTEC comprehensive review. Int J Radiat Oncol Biol Phys 119(2):457\u2013466. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2659_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2008.13.5293","volume":"26","author":"SJ Laughton","year":"2008","unstructured":"Laughton SJ, Merchant TE, Sklar CA et al (2008) Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 26(7):1112\u20131118. https:\/\/doi.org\/10.1200\/JCO.2008.13.5293","journal-title":"J Clin Oncol"},{"issue":"8","key":"2659_CR8","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1210\/jc.2018-01175","volume":"103","author":"CA Sklar","year":"2018","unstructured":"Sklar CA, Antal Z, Chemaitilly W et al (2018) Hypothalamic\u2013pituitary and growth disorders in survivors of childhood cancer: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 103(8):2761\u20132784. https:\/\/doi.org\/10.1210\/jc.2018-01175","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2659_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/cen.13373","volume":"87","author":"C Follin","year":"2017","unstructured":"Follin C, Fjalldal S, Sv\u00e4rd D et al (2017) Microstructure alterations in the hypothalamus in cranially radiated childhood leukaemia survivors but not in craniopharyngioma patients unaffected by hypothalamic damage. Clin Endocrinol (Oxf) 87(4):359\u2013366. https:\/\/doi.org\/10.1111\/cen.13373","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2659_CR10","doi-asserted-by":"publisher","unstructured":"Grippin AJ, McGovern SL (2023) Proton therapy for pediatric diencephalic tumors. Front Oncol 13. https:\/\/doi.org\/10.3389\/fonc.2023.1123082","DOI":"10.3389\/fonc.2023.1123082"},{"issue":"6","key":"2659_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/neuonc\/nov302","volume":"18","author":"BR Eaton","year":"2016","unstructured":"Eaton BR, Esiashvili N, Kim S et al (2016) Endocrine outcomes with proton and photon radiotherapy for standard risk Medulloblastoma. Neuro Oncol 18(6):881\u2013887. https:\/\/doi.org\/10.1093\/neuonc\/nov302","journal-title":"Neuro Oncol"},{"issue":"4","key":"2659_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/08880018.2018.1471111","volume":"35","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz K, Okcu MF, Sonabend R et al (2018) Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with Medulloblastoma. Pediatr Hematol Oncol 35(4):257\u2013267. https:\/\/doi.org\/10.1080\/08880018.2018.1471111","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"2659_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-021-03847-y","volume":"155","author":"KD Aldrich","year":"2021","unstructured":"Aldrich KD, Horne VE, Bielamowicz K et al (2021) Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with Medulloblastoma. J Neurooncol 155(1):93\u2013100. https:\/\/doi.org\/10.1007\/s11060-021-03847-y","journal-title":"J Neurooncol"},{"issue":"3","key":"2659_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1043-2760(00)00359-3","volume":"12","author":"S Rose","year":"2001","unstructured":"Rose S (2001) Cranial irradiation and central hypothyroidism. Trends Endocrinol Metabolism 12(3):97\u2013103","journal-title":"Trends Endocrinol Metabolism"},{"issue":"3","key":"2659_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/pbc.22082","volume":"53","author":"EJ Chow","year":"2009","unstructured":"Chow EJ, Friedman DL, Stovall M et al (2009) Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: A report from the childhood cancer survivor study. Pediatr Blood Cancer 53(3):432\u2013437. https:\/\/doi.org\/10.1002\/pbc.22082","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2659_CR16","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1210\/jc.2003-030209","volume":"88","author":"HM Van Santen","year":"2003","unstructured":"Van Santen HM, Vulsma T, Dijkgraaf MG et al (2003) No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J Clin Endocrinol Metab 88(8):3657\u20133663. https:\/\/doi.org\/10.1210\/jc.2003-030209","journal-title":"J Clin Endocrinol Metab"},{"key":"2659_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1515\/JPEM.2004.17.1.55","volume":"17","author":"SR Rose","year":"2004","unstructured":"Rose SR, Schreiber RE, Kearney NS et al (2004) Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 17:55\u201366","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"12","key":"2659_CR18","first-page":"4472","volume":"84","author":"SR Rose","year":"1999","unstructured":"Rose SR, Lustig RH, Pitukcheewanont P et al (1999) Diagnosis of hidden central hypothyroidism in survivors of childhood Cancer. J Clin Endocrinol Metab 84(12):4472\u20134479","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2659_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7):389\u2013399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2659_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2018","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2018) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"issue":"3","key":"2659_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J De Filette","year":"2019","unstructured":"De Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (2019) A systematic review and Meta-Analysis of Endocrine-Related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(3):145\u2013156. https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"issue":"10","key":"2659_CR22","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1007\/s00432-023-04659-5","volume":"149","author":"S Esteves-Ferreira","year":"2023","unstructured":"Esteves-Ferreira S, Rosinha P (2023) Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features. J Cancer Res Clin Oncol 149(10):7925\u20137932. https:\/\/doi.org\/10.1007\/s00432-023-04659-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"2659_CR23","doi-asserted-by":"publisher","unstructured":"Mizukoshi T, Fukuoka H, Takahashi Y (2022) Immune checkpoint inhibitor-related hypophysitis. Best Pract Res Clin Endocrinol Metab 36(3). https:\/\/doi.org\/10.1016\/j.beem.2022.101668","DOI":"10.1016\/j.beem.2022.101668"},{"key":"2659_CR24","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"2659_CR25","doi-asserted-by":"publisher","unstructured":"Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA (2019) Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab 33(6). https:\/\/doi.org\/10.1016\/j.beem.2019.101371","DOI":"10.1016\/j.beem.2019.101371"},{"key":"2659_CR26","doi-asserted-by":"publisher","first-page":"01","DOI":"10.3389\/fendo.2022.1064146","volume":"13","author":"A Cattoni","year":"2022","unstructured":"Cattoni A, Molinari S, Riva B et al (2022) Thyroid function disorders and secondary cancer following Haematopoietic stem cell transplantation in pediatrics: state of the Art and practical recommendations for a risk-based follow-up. Front Endocrinol (Lausanne) 13:01\u201322. https:\/\/doi.org\/10.3389\/fendo.2022.1064146","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2659_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10555-020-09864-z","volume":"39","author":"U Paetow","year":"2020","unstructured":"Paetow U, Bader P, Chemaitilly W (2020) A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation. Cancer Metastasis Rev 39(1):69\u201378. https:\/\/doi.org\/10.1007\/s10555-020-09864-z","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2659_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/pbc.21634","volume":"51","author":"HK Bailey","year":"2008","unstructured":"Bailey HK, Kappy MS, Giller RH, Gralla J (2008) Time-course and risk factors of hypothyroidism following allogeneic hematopoietic stem cell transplantation (HSCT) in children conditioned with fractionated total body irradiation. Pediatr Blood Cancer 51(3):405\u2013409. https:\/\/doi.org\/10.1002\/pbc.21634","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2659_CR29","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00432-011-1004-2","volume":"137","author":"F Felicetti","year":"2011","unstructured":"Felicetti F, Manicone R, Corrias A et al (2011) Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: A retrospective study from a single institution. J Cancer Res Clin Oncol 137(9):1343\u20131348. https:\/\/doi.org\/10.1007\/s00432-011-1004-2","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2659_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3324\/haematol.2015.140053","volume":"101","author":"C Oudin","year":"2016","unstructured":"Oudin C, Auquier P, Bertrand Y et al (2016) Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. Study. Haematologica 101(6):747\u2013756. https:\/\/doi.org\/10.3324\/haematol.2015.140053","journal-title":"Haematologica"},{"key":"2659_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/0002-9343(82)90411-9","volume":"73","author":"CA Sklar","year":"1962","unstructured":"Sklar CA, Kim TH, Ramsay NK (1962) Thyroid dysfunction among Long-Term survivors of bone marrow transplantation. Am J Med 73:688\u2013694","journal-title":"Am J Med"},{"issue":"6","key":"2659_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1530\/EJE-13-0920","volume":"170","author":"J Graeppi-Dulac","year":"2014","unstructured":"Graeppi-Dulac J, Vlaeminck-Guillem V, Perier-Muzet M, Dalle S, Orgiazzi J (2014) Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. Eur J Endocrinol 170(6):253\u2013262. https:\/\/doi.org\/10.1530\/EJE-13-0920","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2659_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cen.13975","volume":"91","author":"N Makita","year":"2019","unstructured":"Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T (2019) Bexarotene-induced hypothyroidism: characteristics and therapeutic strategies. Clin Endocrinol (Oxf) 91(1):195\u2013200. https:\/\/doi.org\/10.1111\/cen.13975","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"14","key":"2659_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","volume":"340","author":"SI Sherman","year":"1999","unstructured":"Sherman SI, Gopal J, Haugen BR, Chiu AC et al (1999) Central hypothyroidism associated with retinoid X receptor selective ligands. N Engl J Med 340(14):1075\u20131079","journal-title":"N Engl J Med"},{"issue":"3","key":"2659_CR35","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1210\/en.2005-0706","volume":"147","author":"V Sharma","year":"2006","unstructured":"Sharma V, Hays WR, Wood WM et al (2006) Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary- thyroid axis. Endocrinology 147(3):1438\u20131451. https:\/\/doi.org\/10.1210\/en.2005-0706","journal-title":"Endocrinology"},{"issue":"4","key":"2659_CR36","first-page":"481","volume":"11","author":"BR Haugen","year":"1997","unstructured":"Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC (1997) The Thyrotrope-Restricted isoform of the Retinoid-X Receptor-1 mediates 9-Cis-Retinoic acid suppression of Thyrotropin-Promoter activity. Mol Endocrinol 11(4):481\u2013489","journal-title":"Mol Endocrinol"},{"issue":"1","key":"2659_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1507\/endocrj.EJ21-0313","volume":"69","author":"N Toi","year":"2022","unstructured":"Toi N, Kurajoh M, Miyaoka D et al (2022) Bexarotene-Induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-Cell lymphoma patients. Japan Endocr Soc 69(1):101\u2013105","journal-title":"Japan Endocr Soc"},{"issue":"4","key":"2659_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3816\/CLM.2003.n.006","volume":"3","author":"IS Sherman","year":"2003","unstructured":"Sherman IS, Etiology (2003) Diagnosis and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 3(4):249\u2013252","journal-title":"Clin Lymphoma"},{"issue":"9","key":"2659_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092615","volume":"12","author":"V Basile","year":"2020","unstructured":"Basile V, Puglisi S, Calabrese A et al (2020) Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer. Cancers (Basel) 12(9):1\u201315. https:\/\/doi.org\/10.3390\/cancers12092615","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2659_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cen.14345","volume":"94","author":"ME Vikner","year":"2021","unstructured":"Vikner ME, Krogh J, Daugaard G, Andreassen M (2021) Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients. Clin Endocrinol (Oxf) 94(2):141\u2013149. https:\/\/doi.org\/10.1111\/cen.14345","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2659_CR41","first-page":"386","volume":"28","author":"JS Marshall","year":"1968","unstructured":"Marshall JS, Tompkins LS (1968) Effect of o,p\u2019-DDD and similar compounds on thyroxine binding Globulin. Endocr Soc 28:386\u2013392","journal-title":"Endocr Soc"},{"key":"2659_CR42","first-page":"526","volume":"124","author":"AP Van Seters","year":"1991","unstructured":"Van Seters AP, Moolenaar AJ (1991) Mitotane increases the blood levels of Hormone-Binding proteins. Acta Endocrinol (Copenh) 124:526\u2013533","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"4","key":"2659_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.12868","volume":"84","author":"M Russo","year":"2016","unstructured":"Russo M, Scollo C, Pellegriti G et al (2016) Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clin Endocrinol (Oxf) 84(4):614\u2013619. https:\/\/doi.org\/10.1111\/cen.12868","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2659_CR44","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/en.2009-1404","volume":"151","author":"MC Zatelli","year":"2010","unstructured":"Zatelli MC, Gentilin E, Daffara F et al (2010) Therapeutic concentrations of mitotane (o,p\u2032-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151(6):2453\u20132461. https:\/\/doi.org\/10.1210\/en.2009-1404","journal-title":"Endocrinology"},{"key":"2659_CR45","doi-asserted-by":"publisher","unstructured":"Bianchini M, Puliani G, Chiefari A, Mormando M, Lauretta R, Appetecchia M (2021) Metabolic and endocrine toxicities of mitotane: A systematic review. Cancers (Basel) 13(19). https:\/\/doi.org\/10.3390\/cancers13195001","DOI":"10.3390\/cancers13195001"},{"issue":"9","key":"2659_CR46","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1210\/clinem\/dgad115","volume":"108","author":"J Poirier","year":"2023","unstructured":"Poirier J, Godemel S, Mourot A et al (2023) Central hypothyroidism is frequent during mitotane therapy in adrenocortical Cancer patients: prevalence and timeline. J Clin Endocrinol Metab 108(9):2336\u20132342. https:\/\/doi.org\/10.1210\/clinem\/dgad115","journal-title":"J Clin Endocrinol Metab"},{"key":"2659_CR47","doi-asserted-by":"crossref","unstructured":"Alexopoulou O, Beguin C, De Nayer P, Maiter D (2004) Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during Follow-up in adult patients. Eur J  Endocrinol 150(2):1\u20138","DOI":"10.1530\/eje.0.1500001"},{"issue":"6","key":"2659_CR48","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1373\/clinchem.2009.140194","volume":"56","author":"LM Thienpont","year":"2010","unstructured":"Thienpont LM, Van Uytfanghe K, Beastall G et al (2010) Report of the IFCC working group for standardization of thyroid function tests; part 2: free thyroxine and free Triiodothyronine. Clin Chem 56(6):912\u2013920. https:\/\/doi.org\/10.1373\/clinchem.2009.140194","journal-title":"Clin Chem"},{"issue":"5","key":"2659_CR49","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1210\/endrev\/bnab040","volume":"43","author":"L Van Iersel","year":"2022","unstructured":"Van Iersel L, Mulder RL, Denzer C et al (2022) Hypothalamic-Pituitary and other endocrine surveillance among childhood Cancer survivors. Endocr Rev 43(5):794\u2013823. https:\/\/doi.org\/10.1210\/endrev\/bnab040","journal-title":"Endocr Rev"},{"issue":"9","key":"2659_CR50","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1210\/jc.2012-1616","volume":"97","author":"L Persani","year":"2012","unstructured":"Persani L (2012) Central hypothyroidism: pathogenic, diagnostic and therapeutic challenges. J Clin Endocrinol Metab 97(9):3068\u20133078. https:\/\/doi.org\/10.1210\/jc.2012-1616","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2659_CR51","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1210\/jc.2003-030943","volume":"88","author":"A Mehta","year":"2003","unstructured":"Mehta A, Hindmarsh PC, Stanhope RG, Brain CE, Preece MA, Dattani MT (2003) Is the Thyrotropin-Releasing hormone test necessary in the diagnosis of central hypothyroidism in children. J Clin Endocrinol Metab 88(12):5696\u20135703. https:\/\/doi.org\/10.1210\/jc.2003-030943","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2659_CR52","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2659_CR53","doi-asserted-by":"publisher","first-page":"R44","DOI":"10.1530\/EC-18-0515","volume":"8","author":"L Persani","year":"2019","unstructured":"Persani L, Cangiano B, Bonomi M (2019) The diagnosis and management of central hypothyroidism in 2018. Endocr Connect 8(2):R44\u2013R54. https:\/\/doi.org\/10.1530\/EC-18-0515","journal-title":"Endocr Connect"},{"issue":"23","key":"2659_CR54","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1056\/NEJM200106073442302","volume":"344","author":"BM Arafah","year":"2001","unstructured":"Arafah BM (2001) Increased need for thyroxine in women with hypothyroidism during Estrogen therapy. N Engl J Med 344(23):1743\u20131749","journal-title":"N Engl J Med"},{"issue":"11","key":"2659_CR55","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1210\/jc.2007-0941","volume":"92","author":"MRA Martins","year":"2007","unstructured":"Martins MRA, Doin FC, Komatsu WR, Barros-Neto TL, Moises VA, Abucham J (2007) Growth hormone replacement improves thyroxine biological effects: implications for management of central hypothyroidism. J Clin Endocrinol Metab 92(11):4144\u20134153. https:\/\/doi.org\/10.1210\/jc.2007-0941","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2659_CR56","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrendo.2017.47","volume":"13","author":"P Beck-Peccoz","year":"2017","unstructured":"Beck-Peccoz P, Rodari G, Giavoli C, Lania A (2017) Central hypothyroidism - a neglected thyroid disorder. Nat Rev Endocrinol 13(10):588\u2013598. https:\/\/doi.org\/10.1038\/nrendo.2017.47","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2659_CR57","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S2213-8587(14)70081-6","volume":"3","author":"RM Paragliola","year":"2015","unstructured":"Paragliola RM, Prete A, Kaplan PW, Corsello SM, Salvatori R (2015) Treatment of hypopituitarism in patients receiving antiepileptic drugs. Lancet Diabetes Endocrinol 3(2):132\u2013140. https:\/\/doi.org\/10.1016\/S2213-8587(14)70081-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2659_CR58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/endo-71-3-496","volume":"71","author":"JH Oppenheimer","year":"1962","unstructured":"Oppenheimer JH, Tavernetti RR (1962) Studies on the Thyroxine-Diphenylhydantoin interaction: effect of 5,5\u2019-Diphenylhydantoin on the displacement of L-Thyroxine from Thyroxine-Binding Globulin (TBG). Endocr Soc 71:496\u2013504","journal-title":"Endocr Soc"},{"issue":"3","key":"2659_CR59","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2006","unstructured":"Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61(3):246\u2013255. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02529.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2659_CR60","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00228-005-0056-0","volume":"61","author":"M Strolin Benedetti","year":"2005","unstructured":"Strolin Benedetti M, Whomsley R, Baltes E, Tonner F (2005) Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 61(12):863\u2013872. https:\/\/doi.org\/10.1007\/s00228-005-0056-0","journal-title":"Eur J Clin Pharmacol"},{"key":"2659_CR61","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3109\/00365517809104880","volume":"38","author":"K Rootwelt","year":"1978","unstructured":"Rootwelt K, Ganes T, Johannessen I (1978) Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and Thyrotropin in humans. Scand J Clin Lab Invest 38:731\u2013736","journal-title":"Scand J Clin Lab Invest"},{"key":"2659_CR62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1528-1157.1978.tb04498.x","volume":"19","author":"H Fichsel","year":"1978","unstructured":"Fichsel H, Knopfle G (1978) Effects of anticonvulsant drugs on thyroid hormones in epileptic children. Epilepsia 19:323\u2013336","journal-title":"Epilepsia"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02659-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:14:37Z","timestamp":1766999677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02659-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2659"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02659-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to the incorrect funding text was published in the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}